» Articles » PMID: 33892503

Transcriptomic Changes and the Roles of Cannabinoid Receptors and PPARγ in Developmental Toxicities Following Exposure to Δ9-Tetrahydrocannabinol and Cannabidiol

Overview
Journal Toxicol Sci
Specialty Toxicology
Date 2021 Apr 23
PMID 33892503
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Human consumption of cannabinoid-containing products during early life or pregnancy is rising. However, information about the molecular mechanisms involved in early life stage Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) toxicities is critically lacking. Here, larval zebrafish (Danio rerio) were used to measure THC- and CBD-mediated changes on transcriptome and the roles of cannabinoid receptors (Cnr) 1 and 2 and peroxisome proliferator activator receptor γ (PPARγ) in developmental toxicities. Transcriptomic profiling of 96-h postfertilization (hpf) cnr+/+ embryos exposed (6 - 96 hpf) to 4 μM THC or 0.5 μM CBD showed differential expression of 904 and 1095 genes for THC and CBD, respectively, with 360 in common. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched in the THC and CBD datasets included those related to drug, retinol, and steroid metabolism and PPAR signaling. The THC exposure caused increased mortality and deformities (pericardial and yolk sac edemas, reduction in length) in cnr1-/- and cnr2-/- fish compared with cnr+/+ suggesting Cnr receptors are involved in protective pathways. Conversely, the cnr1-/- larvae were more resistant to CBD-induced malformations, mortality, and behavioral alteration implicating Cnr1 in CBD-mediated toxicity. Behavior (decreased distance travelled) was the most sensitive endpoint to THC and CBD exposure. Coexposure to the PPARγ inhibitor GW9662 and CBD in cnr+/+ and cnr2-/- strains caused more adverse outcomes compared with CBD alone, but not in the cnr1-/- fish, suggesting that PPARγ plays a role in CBD metabolism downstream of Cnr1. Collectively, PPARγ, Cnr1, and Cnr2 play important roles in the developmental toxicity of cannabinoids with Cnr1 being the most critical.

Citing Articles

Evaluation of the Efficacy of a Full-Spectrum Low-THC Plant Extract Using In Vitro Models of Inflammation and Excitotoxicity.

Ross-Munro E, Isikgel E, Fleiss B Biomolecules. 2024; 14(11).

PMID: 39595610 PMC: 11592195. DOI: 10.3390/biom14111434.


Cannabidiol (CBD) modulates the transcriptional profile of ethanol-exposed human dermal fibroblast cells.

Gurgul A, Zurowski J, Szmatola T, Kucharski M, Sawicki S, Semik-Gurgul E J Appl Genet. 2024; 65(4):773-796.

PMID: 39466591 PMC: 11561130. DOI: 10.1007/s13353-024-00915-7.


Exploring the Potential of Synthetic Cannabinoids: Modulation of Biological Activity of Normal and Cancerous Human Colon Epithelial Cells.

Paduch R, Szwaczko K, Dziuba K, Wiater A Cells. 2024; 13(19.

PMID: 39404380 PMC: 11475369. DOI: 10.3390/cells13191616.


Liver Transcriptomic Profiles of Ruminant Species Fed Spent Hemp Biomass Containing Cannabinoids.

Irawan A, Bionaz M Genes (Basel). 2024; 15(7).

PMID: 39062742 PMC: 11275923. DOI: 10.3390/genes15070963.


Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries.

Aychman M, Goldman D, Kaplan J Front Neurol. 2023; 14:1087011.

PMID: 36816569 PMC: 9932048. DOI: 10.3389/fneur.2023.1087011.


References
1.
De Petrocellis L, Ligresti A, Moriello A, Allara M, Bisogno T, Petrosino S . Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2010; 163(7):1479-94. PMC: 3165957. DOI: 10.1111/j.1476-5381.2010.01166.x. View

2.
Lu H, Mackie K . An Introduction to the Endogenous Cannabinoid System. Biol Psychiatry. 2015; 79(7):516-25. PMC: 4789136. DOI: 10.1016/j.biopsych.2015.07.028. View

3.
Grant K, Petroff R, Isoherranen N, Stella N, Burbacher T . Cannabis use during pregnancy: Pharmacokinetics and effects on child development. Pharmacol Ther. 2017; 182:133-151. PMC: 6211194. DOI: 10.1016/j.pharmthera.2017.08.014. View

4.
Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Batkai S . Endocannabinoids and the control of energy homeostasis. J Biol Chem. 2008; 283(48):33021-5. PMC: 2586261. DOI: 10.1074/jbc.R800012200. View

5.
Stancic A, Jandl K, Hasenohrl C, Reichmann F, Marsche G, Schuligoi R . The GPR55 antagonist CID16020046 protects against intestinal inflammation. Neurogastroenterol Motil. 2015; 27(10):1432-45. PMC: 4587547. DOI: 10.1111/nmo.12639. View